Expert consensus provides guidelines for managing cardiometabolic risk in patients with prostate cancer on ADT
Experts Establish Guidelines for Heart Health in Prostate Cancer Patients
This expert consensus guideline addresses the management of cardiometabolic risk in patients with prostate cancer undergoing androgen depriv…
New expert guidelines provide a framework for managing heart and metabolic risks for patients undergoing specific prostate cancer treatments…
Enzalutamide added to ADT improves survival in APIC-negative metastatic hormone-sensitive prostate cancer
Trial shows enzalutamide helps specific patients with prostate cancer
This randomized controlled trial analyzed 492 patients with metastatic hormone-sensitive prostate cancer to evaluate the impact of the APIC …
A new analysis shows that a specific biomarker can help doctors identify which prostate cancer patients may benefit most from enzalutamide t…
Precision oncology and biomarker-driven strategies enable personalized management of prostate cancer through multiple pathways
New research reveals complex pathways driving prostate cancer growth
This systematic review synthesizes the role of genomic classifiers and molecular signatures in prostate cancer management. The review highli…
New research shows that prostate cancer involves many interconnected pathways, opening doors for more personalized treatment options for pat…
Osteoporosis prevalence is 22.0% and low bone mass is 41.7% in men with prostate cancer
Prostate Cancer Treatment Linked to Higher Risk of Bone Loss
This meta-analysis of 91,913 adult men with prostate cancer found a 22.0% prevalence of osteoporosis and 41.7% prevalence of low bone mass. …
Men undergoing treatment for prostate cancer may face a significant risk of low bone mass and osteoporosis during their care.
Maximal androgen blockade increases fracture risk by odds ratio 1.5 to 2.4 compared to ADT
Managing Bone Health Risks for Men Receiving Advanced Prostate Cancer Treatments
This meta-analysis of 16162 patients with prostate cancer found that maximal androgen blockade (MAB) significantly increases the risk of fra…
New research shows that combining certain hormone therapies for prostate cancer can increase fracture risks, making bone protection very imp…
STAMINA lifestyle intervention improves FACT-P and FACIT-F scores in men on ADT
Supervised exercise improves quality of life for prostate cancer patients
This randomized controlled trial of 700 men with prostate cancer on androgen deprivation therapy found that the STAMINA lifestyle interventi…
A new study shows that a year of supervised exercise and dietary advice helps men on hormone therapy feel better and less tired.
Androgen deprivation therapy is associated with an OR 1.34 for acute kidney injury
Androgen deprivation therapy linked to higher risk of kidney injury
This meta-analysis of 72,980 patients with prostate cancer found that androgen deprivation therapy (ADT) is significantly associated with an…
A large review of over 70,000 patients suggests that certain prostate cancer treatments may be linked to a higher risk of acute kidney injur…
Dose Escalated Radiotherapy Combined With Androgen Deprivation Improves Outcomes in High Risk Prostate Cancer
Higher radiation doses may improve long-term outcomes for prostate cancer
A Phase 3 trial demonstrates that 80 Gy of radiotherapy plus long-term ADT significantly improves 10-year progression-free survival.
A large trial shows that a higher dose of radiation combined with hormone therapy may help men with high-risk prostate cancer stay cancer-fr…
Trial protocol evaluates 9-month ADT plus ARTA for high-risk prostate cancer non-inferiority
New trial tests shorter hormone therapy for high-risk prostate cancer
This Phase II trial protocol evaluates 9 months of androgen deprivation therapy (ADT) plus 6 months of an androgen receptor-targeted agent (…
A new clinical trial is testing if a shorter, more intense hormone treatment can work just as well as standard care for high-risk prostate c…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Lu-PSMA-617 combined with ADT and ARPI reduced radiographic progression risk by 28%
New Treatment Options for Men with Advanced Prostate Cancer
This Phase 3 randomized controlled trial of 1144 patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate …
A large study shows that adding a specific radioactive treatment to standard hormone therapy can help slow cancer growth.
Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
Lead-in therapy may reduce severe low white blood cell counts
This post hoc analysis of a phase 3 trial and real-world validation study evaluated lead-in androgen-deprivation therapy (ADT) for patients …
A new look at clinical data suggests that a lead-in hormone treatment can help prevent serious low white blood cell counts in prostate cance…
All androgen deprivation therapy Articles
- Expert consensus provides guidelines for managing cardiometabolic risk in patients with prostate cancer on ADT
- Enzalutamide added to ADT improves survival in APIC-negative metastatic hormone-sensitive prostate cancer
- Precision oncology and biomarker-driven strategies enable personalized management of prostate cancer through multiple pathways
- Osteoporosis prevalence is 22.0% and low bone mass is 41.7% in men with prostate cancer
- Maximal androgen blockade increases fracture risk by odds ratio 1.5 to 2.4 compared to ADT
- STAMINA lifestyle intervention improves FACT-P and FACIT-F scores in men on ADT
- Androgen deprivation therapy is associated with an OR 1.34 for acute kidney injury
- Trial protocol evaluates 9-month ADT plus ARTA for high-risk prostate cancer non-inferiority
- Dose Escalated Radiotherapy Combined With Androgen Deprivation Improves Outcomes in High Risk Prostate Cancer
- Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
- Lu-PSMA-617 combined with ADT and ARPI reduced radiographic progression risk by 28%
- Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
- Salvage radiotherapy combined with androgen deprivation therapy improves biochemical progression-free survival in prostate cancer
- Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
- Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
- Time to biochemical progression predicts second events in high-risk prostate cancer
- Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
- Phase II trial of CyberKnife SBRT and androgen deprivation therapy in unfavorable intermediate- to high-risk localized prostate cancer
- MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
- Systematic review finds neoadjuvant chemohormonal therapy improves biochemical progression-free survival in locally advanced prostate cancer
- Expert panel agrees on early detection and ARPI/ADT role for high-risk prostate cancer BCR